Kaken Pharmaceutical Co., Ltd.
4521.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$140.3B
Close$
Share Statistics
| Market cap | $140.30 Billion |
|---|---|
| Enterprise Value | $86.80 Billion |
| Dividend Yield | $190.00 (5.13%) |
| Earnings per Share | $56.55 |
| Beta | 0.13 |
| Outstanding Shares | 37,868,209 |
Return
| Return on Equity | 6.76% |
|---|---|
| Return on Assets | 5.52% |
| Return on Invested Capital | 6.79% |
Valuation & Multiples
| P/E Ratio | 13.61 |
|---|---|
| PEG | 0.45 |
| Price to Sales | 1.59 |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | 0.98 |
| Enterprise Value to EBIT | 7.91 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$29.37 B
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$30.28 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kaken Pharmaceutical Co., Ltd.
1,114 employees
CEO: Hiroyuki Horiuchi Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensiv...